现代医药卫生
現代醫藥衛生
현대의약위생
MODERN MEDICINE HEALTH
2014年
10期
1457-1458,1460
,共3页
痴呆,血管性/药物疗法%痴呆,血管性/并发症%精神障碍/药物疗法%精神障碍/并发症%胆碱酯酶抑制剂/治疗应用%哌仑西平/类似物和衍生物
癡呆,血管性/藥物療法%癡呆,血管性/併髮癥%精神障礙/藥物療法%精神障礙/併髮癥%膽堿酯酶抑製劑/治療應用%哌崙西平/類似物和衍生物
치태,혈관성/약물요법%치태,혈관성/병발증%정신장애/약물요법%정신장애/병발증%담감지매억제제/치료응용%고륜서평/유사물화연생물
Dementia,vascular/drug therapy%Dementia,vascular/complications%Mental disorders/drug therapy%Mental disorders/complications%Cholinesterase inhibitors/therapeutic use%Pirenzepine/analogs&derivatives
目的：探讨不同剂量多奈哌齐与新型抗精神病药奥氮平联合使用治疗伴精神行为症状血管性痴呆（VaD）的远期疗效及安全性。方法选择2012年2月至2014年1月该院收治的80例伴精神行为症状VaD患者作为研究对象。依门诊号或住院号的末位数奇偶随机分组，奇数者为研究组，偶数者为对照组，每组各40例。研究组（大剂量组）服用多奈哌齐10 mg/d，奥氮平10 mg/d；对照组（小剂量组）服用多奈哌齐5 mg/d，奥氮平5 mg/d。治疗期间对两组患者进行不良反应量表（TESS）、简明精神病量表（BPRS）、Hachinski缺血指数记分表（HIS）、痴呆简易筛查量表（BSSD）、日常生活能力量表（ADL）评分比较。结果研究组治疗后3、6、9、12个月BPRS评分变化与对照组比较，差异有统计学意义（P＜0.05）；研究组治疗12个月后HIS、BSSD、ADL评分变化与对照组比较，差异均有统计学意义（P＜0.05）；两组患者治疗及随访期间无不良反应发生。结论多奈哌齐联合奥氮平治疗伴精神行为症状VaD远期疗效明显、不良反应小、安全可靠，值得在临床上推广应用。
目的：探討不同劑量多奈哌齊與新型抗精神病藥奧氮平聯閤使用治療伴精神行為癥狀血管性癡呆（VaD）的遠期療效及安全性。方法選擇2012年2月至2014年1月該院收治的80例伴精神行為癥狀VaD患者作為研究對象。依門診號或住院號的末位數奇偶隨機分組，奇數者為研究組，偶數者為對照組，每組各40例。研究組（大劑量組）服用多奈哌齊10 mg/d，奧氮平10 mg/d；對照組（小劑量組）服用多奈哌齊5 mg/d，奧氮平5 mg/d。治療期間對兩組患者進行不良反應量錶（TESS）、簡明精神病量錶（BPRS）、Hachinski缺血指數記分錶（HIS）、癡呆簡易篩查量錶（BSSD）、日常生活能力量錶（ADL）評分比較。結果研究組治療後3、6、9、12箇月BPRS評分變化與對照組比較，差異有統計學意義（P＜0.05）；研究組治療12箇月後HIS、BSSD、ADL評分變化與對照組比較，差異均有統計學意義（P＜0.05）；兩組患者治療及隨訪期間無不良反應髮生。結論多奈哌齊聯閤奧氮平治療伴精神行為癥狀VaD遠期療效明顯、不良反應小、安全可靠，值得在臨床上推廣應用。
목적：탐토불동제량다내고제여신형항정신병약오담평연합사용치료반정신행위증상혈관성치태（VaD）적원기료효급안전성。방법선택2012년2월지2014년1월해원수치적80례반정신행위증상VaD환자작위연구대상。의문진호혹주원호적말위수기우수궤분조，기수자위연구조，우수자위대조조，매조각40례。연구조（대제량조）복용다내고제10 mg/d，오담평10 mg/d；대조조（소제량조）복용다내고제5 mg/d，오담평5 mg/d。치료기간대량조환자진행불량반응량표（TESS）、간명정신병량표（BPRS）、Hachinski결혈지수기분표（HIS）、치태간역사사량표（BSSD）、일상생활능역량표（ADL）평분비교。결과연구조치료후3、6、9、12개월BPRS평분변화여대조조비교，차이유통계학의의（P＜0.05）；연구조치료12개월후HIS、BSSD、ADL평분변화여대조조비교，차이균유통계학의의（P＜0.05）；량조환자치료급수방기간무불량반응발생。결론다내고제연합오담평치료반정신행위증상VaD원기료효명현、불량반응소、안전가고，치득재림상상추엄응용。
Objective To explore the long-term results and security of different doses of donepezil combined with novel antipsychotic drugs-olanzapine in treating behavioral and psychological symptoms of vascular dementia (VaD). Methods This study selected 80 patients with behavioral and psychological symptoms of VaD as research objects,who were received in the hospital from February 2012 to January 2014. According to the last number of admission number (AD),all the patients were divided into research group(with odd number) and control group(with even number),40 cases in each group. The research group(high-dose group) was administered with 10 mg donepezil and 10 mg olanzapine daily;the control group(low-dose group) was taken 5 mg donepezil and 5 mg olanzapine daily. During treatment ,comparison between the two group was conducted on the Treatment Emer-gent Symptom Scale (TESS),Brief Psychiatric Rating Scale (BPRS),Hachinski Ischemic Score (HIS),Brief Screening Scale for Dementia(BSSD) and activity of daily living scale(ADL). Results The difference between the research group and control group on BRPS changes 3,6,9,12 months after treatment was statistically significant(P<0.05). 12 months after treatment,the changes of HIS,BSSD and ADL between the two groups had statistically significant difference (P<0.05). No adverse reactions occurred in patients of the two groups during the treatment and the follow-up. Conclusion Donepezil combined with olanzapine has obvious effect with less adverse reaction on behavior and physical symptoms of VaD ,it is worthy of clinical promotion due to safety and security.
